Abstract
Background
Oncrasin-1 is a small molecule which was identified from a screen of KRAS mutant cancer cells and has shown specificity for KRAS mutant cell killing. We aimed to develop a radiolabelled form of Oncrasin-1 to enable in-vivo imaging of mutant KRAS expression in malignant tumours. This work outlines the synthesis of 3 fluorinated derivatives and development of iodonium salt and boronic ester precursors for radiolabelling with the 18F isotope.
Results
In our hands, synthesis of iodonium salts were not easily accessible due to the 3-carbaldehyde indole structure being preferentially oxidized by conditions required for iodonium salt formation, rather than benzyl iodide. Synthesis and radiolabelling of boronic acid pinacol ester precursors were successful, with the products being obtained in yields of 10.76% ± 0.96% (n = 5), 14.7% ±8.58% (n = 3) and 14.92% ±3.9% (n = 3) for 18F KAM001, 18F KAM002 and 18F KAM003 respectively, with radiochemical purity of greater than 99%.
Conclusions
The successful synthesis of these tracers has been undertaken utilizing boronic ester radio-fluorination methods and will allow for investigation of Oncrasin based molecules as potential diagnostics for cancers expressing mutant KRAS protein.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Goh, Yit Wooi 2 ; White, Jonathan M 3
; Scott, Andrew M 4
; Ackermann Uwe 4 1 La Trobe University, The Olivia Newton-John Cancer Research Insititute, and School of Cancer Medicine, Heidelberg, Australia (GRID:grid.1018.8) (ISNI:0000 0001 2342 0938); Austin Health, Department of Molecular Imaging and Therapy, Heidelberg, Australia (GRID:grid.410678.c); The University of Melbourne, School of Chemistry, Bio21 Institute, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
2 Melbourne, Australia (GRID:grid.1008.9)
3 The University of Melbourne, School of Chemistry, Bio21 Institute, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
4 La Trobe University, The Olivia Newton-John Cancer Research Insititute, and School of Cancer Medicine, Heidelberg, Australia (GRID:grid.1018.8) (ISNI:0000 0001 2342 0938); Austin Health, Department of Molecular Imaging and Therapy, Heidelberg, Australia (GRID:grid.410678.c); The University of Melbourne, Faculty of Medicine, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)




